Report
EUR 13.68 For Business Accounts Only

HUBEI JUMPCAN PHARM.CTD. suffers a double requalification, which weighs heavily on its rating, now at Slightly Negative.

The independent financial analyst theScreener just downgraded the general evaluation of HUBEI JUMPCAN PHARM.CTD. (CN), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title loses a star(s) and now shows 1 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Slightly Negative. As of the analysis date April 24, 2020, the closing price was CNY 20.21 and its target price was estimated at CNY 18.46.
Underlying
HUBEI JUMPCAN PHARMACEUTICAL CO. LTD Class A

Hubei Hongcheng General Machinery is engaged in the manufacture and sale of various kinds of valves, irrigation machineries, metal structure parts, environmental protection equipments, machine tools, and nonferrous metals; the export of self-produced mechanical and electrical products; the import of raw materials for scientific research, machineries, equipments, spare parts and technology; the processing of imported materials; general-purpose machineries technical research; and property leasing. Through its subsidiaries, Co. is also engaged in freight transportation; provision of Chinese catering services; the sale of household appliances and textile products; and printing businesses.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch